3 completed, 1 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Unknown 1 |
Follow Peptides: new trials by email Literature Review of Peptides trials Research Report on Peptides
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide - Melanoma, Skin Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 4 | 2008-12-01 | 2015-10-28 |
| A Study With Peptide Vaccination in Treating Patients With Esophageal Cancer peptide - Esophageal Cancer | Phase 2 | Unknown | University of Yamanashi | 60 | 2008-11-01 | 2009-10-15 |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers WT1:126-134, PR1:169-177 Peptide, GM-CSF (Sargramostim) - Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 10 | 2007-06-01 | 2021-07-12 |
| Melanoma Vaccine With Peptides and Leuprolide Leuprolide, GP100: 209-217(210M) Peptide, MAGE-3 Peptide - Melanoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 98 | 2005-11-01 | 2019-10-16 |
Melanoma (2) · Skin Neoplasms (2) · Esophageal Neoplasms (1) · Eye Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Uveal Melanoma (1)
M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · University of Yamanashi (1)
United States (3) · Japan (1)
Koji Kono, MD.PhD (1) · Minocher Battiwalla, MD (1) · Patrick Hwu, MD (1) · Steven Rosenberg, M.D. (1)